CDC to Award Contract to Emergent for 9 Million Doses of Smallpox Vaccine

Notable Biodefense Contracts

The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price contract to Emergent Biodefense Operations Lansing LLC.

The Government intends to purchase 9 Million doses of Food And Drug Administration (FDA) licensed ACAM2000 Smallpox Vaccine, at the time of award with the option to purchase additional doses. This contract will have a 12 month base period and four 12 month option periods.

Emergent is the only FDA licensed provider of ACAM2000 Smallpox Vaccine and therefore is the only source capable to provide this requirement to the Government. Emergent’s manufacturing processes have been validated and are approved by the FDA, (STN 125158, License #1815).

Containing Ebola in a Conflict Zone, Algorithm vs. Animal Tox Testing, Measles Outbreak in Brazil

Zika Virus Particles

First Human Trial of Live, Attenuated Zika Vaccine Begins